Stevanato Group S.p.A.
NYSE:STVNMedical - Instruments & Supplies
+$0.67 today
- Market cap
- $4.20B
- Beta
- 0.78
- P/E (TTM)
- 29.9
- EPS (TTM)
- $0.52
- Dividend yield
- 0.35%
Volume 0.61M
Average 0.52M
STVN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Stevanato Group S.p.A.NYSE: STVN
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of €6.2M rose 2.6% year over year, behind the +5.3% change in trailing-twelve-month research & development. Sequentially, it rose 6.1% from the prior quarter. Over 3 fiscal years it compounded at -10.8% a year.
Context
- Research & development amounted to 2.1% of revenue in FY2025, down 0.7 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +2.6% toward the trailing-twelve-month pace of +5.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
EUR · from the income statement
- Latest · FY2025
- 24.4M EUR
- Year-over-year change
- -23.0%
- 4-year CAGR
- -4.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.4M | -23.0% |
| FY2024 | 2024-12-31 | 31.67M | -11.2% |
| FY2023 | 2023-12-31 | 35.67M | +3.7% |
| FY2022 | 2022-12-31 | 34.39M | +16.1% |
| FY2021 | 2021-12-31 | 29.62M | — |
Research & Development vs competitors
How STVN compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5.3% is the 4th highest of 7, against a peer median of +6.8%.
- Research & development amounts to 2.1% of revenue for STVN, versus a peer median of 7.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $404M USD | +12.5% | +6.5% | 7.6% | |
| LTM Jun 2026 | $325.34M USD | — | — | 8.3% | |
| LTM Mar 2026 | $316.16M USD | +24.7% | +68.9% | — | |
| LTM Jun 2026 | $195.47M USD | +23.6% | -2.0% | 7.5% | |
| LTM Jun 2026 | $187.86M USD | -3.5% | +46.8% | 24.2% | |
| LTM Apr 2026 | $122.5M USD | -38.4% | -12.9% | 7.9% | |
| LTM Sep 2026 | $96.93M USD | +1.0% | +8.8% | 6.0% | |
| LTM Jun 2026 | €25.44M EUR | +5.3% | -10.8% | 2.1% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding STVN) | — | +6.8% | +7.7% | 7.5% | |
Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 843.92M | 983.68M | 1.09B | 1.1B | 1.14B |
| Cost of Revenue | 578.52M | 663.88M | 745.46M | 801.72M | 809.15M |
| Gross Profit | 265.41M | 319.8M | 339.89M | 302.32M | 330.33M |
| Gross Margin | 31.4% | 32.5% | 31.3% | 27.4% | 29.0% |
| Research & Development | 29.62M | 34.39M | 35.67M | 31.67M | 24.4M |
| Selling, General & Admin | 82.95M | 111.83M | 113.92M | 118.6M | 122.85M |
| Operating Expenses | 103.18M | 127.37M | 139.17M | 141.18M | 147.25M |
| Depreciation & Amortization | 56.38M | 64.82M | 78.48M | 80.65M | 88.57M |
| EBITDA | 226.93M | 256.4M | 272.35M | 247.8M | 292.01M |
| EBITDA Margin | 26.9% | 26.1% | 25.1% | 22.4% | 25.6% |
| Operating Income | 162.23M | 192.43M | 200.72M | 161.14M | 183.08M |
| Operating Margin | 19.2% | 19.6% | 18.5% | 14.6% | 16.1% |
| Interest Income | 548K | 648K | 792K | 1.72M | 12.49M |
| Interest Expense | 4.87M | 3.94M | 4.32M | 6.86M | 21.8M |
| Other Income / Expenses | 3.45M | (4.79M) | (11.17M) | (854K) | (1.44M) |
| Income Before Tax | 165.67M | 187.64M | 189.55M | 160.29M | 181.64M |
| Pre-Tax Margin | 19.6% | 19.1% | 17.5% | 14.5% | 15.9% |
| Income Tax Expense | 31.4M | 44.63M | 43.86M | 42.52M | 47.35M |
| Net Income | 134.32M | 142.85M | 145.63M | 117.78M | 134.28M |
| Net Margin | 15.9% | 14.5% | 13.4% | 10.7% | 11.8% |
| EPS (Basic) | 0.53 | 0.53 | 0.55 | 0.43 | 0.49 |
| EPS (Diluted) | 0.53 | 0.53 | 0.55 | 0.43 | 0.49 |
| Weighted Avg Shares | 264.7M | 264.7M | 264.95M | 272.87M | 273M |
| Weighted Avg Shares (Diluted) | 264.7M | 264.7M | 264.98M | 272.88M | 273M |
Stevanato Group S.p.A.
NYSE:STVN
Intrinsic Alpha fair value
Locked
Current Price
$15.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.